Skip to nav Skip to content

BloodThe multispecialty team in the Blood and Marrow Transplant and Cellular Immunotherapy Program (BMT CI) can offer your patients comprehensive services, including: 

  • Autologous transplant, using patients’ own stem cells
  • Allogeneic transplant, using stem cells from a family member, unrelated matched or unmatched donor, or umbilical cord blood
  • Immunotherapy in many forms including:
    • Cellular immunotherapy, also called adoptive cell therapy
      • Chimeric antigen receptor (CAR) T cell therapy, using patients’ own T cells redirected against their tumor
      • Tumor-infiltrating lymphocyte (TIL) therapy
      • T-cell receptor (TCR) therapy
      • Dendritic cell (DC) vaccines
    • Immune checkpoint inhibitors
      • Monoclonal antibodies
    • T-cell engaging therapies (TCE)
    • Moffitt's Immune Cell Therapy (ICE-T) Service, offering specialized clinical care for patients receiving immunotherapies
  • Access to our extensive stem cell transplant and immunotherapy clinical trials
  • Comprehensive services for the identification of unrelated donors
  • Transplantation for adults over age 70 who have an indication for BMT
  • Treatment of post-transplantation complications including graft-versus-host disease
  • Nutrition consults
  • Specialty pharmacy
  • Supportive care

Different types of treatment and technology are available for patients who need blood and marrow transplants:

  • Syngeneic stem cell transplant
  • Hematopoietic cell transplant (HCT) / Bone marrow transplant (BMT)
  • T-cell replete haploidentical transplant
  • Myeloablative (high-intensity) stem cell transplant
  • Reduced-intensity transplant
  • Peripheral blood stem cell transplant
  • Outpatient transplant

Medically reviewed by Ciara Freeman, MD, PhD